Description

Tirzepatide (Dual GIP/GLP‑1 Receptor Agonist)

Description

• Tirzepatide is a synthetic peptide that agonizes both glucose‑dependent insulinotropic polypeptide (GIP) and glucagon‑like peptide‑1 (GLP‑1) receptors.
• Investigational/approved for glycemic control in type 2 diabetes (brand: Mounjaro) and approved for chronic weight management in some regions (brand: Zepbound).

Key benefits

• Produces substantial reductions in body weight through appetite suppression and slowed gastric emptying.
• Improves glycemic control by enhancing glucose‑dependent insulin secretion and lowering fasting and postprandial glucose.
• Can improve cardiometabolic risk markers (e.g., blood pressure, lipids) in clinical trials.

Primary uses

• Treatment of type 2 diabetes mellitus to improve glycemic control (as adjunct to diet and exercise).
• Pharmacologic therapy for chronic weight management in adults meeting prescribing criteria (where approved).
• Used under prescription with clinical monitoring.

Who it’s for

• Adults with type 2 diabetes needing additional glycemic control.
• Adults with obesity or overweight with weight‑related comorbidities who meet eligibility for prescription weight‑loss therapy.
• Not for use in type 1 diabetes, diabetic ketoacidosis, or without medical oversight.

Suggested use

• Administered by once‑weekly subcutaneous injection following product‑specific titration schedules to improve tolerability.
• Initiate and titrate per prescribing information; monitor glycemic response and adjust concomitant glucose‑lowering medications to reduce hypoglycemia risk.

Safety and storage

• Common adverse effects: nausea, vomiting, diarrhea, constipation, abdominal pain; often attenuate with gradual dose escalation.
• Serious but less common risks: pancreatitis, gallbladder disease, acute kidney injury (from volume depletion), and potential thyroid C‑cell tumor signals seen in rodents. Contraindicated in individuals with personal/family history of medullary thyroid carcinoma (MTC) or MEN2 syndromes.
• Use caution with insulin or insulin secretagogues to avoid hypoglycemia—dose adjustments may be needed.
• Store refrigerated unopened; follow product label for in‑use storage and handling.

Quick facts

• Mechanism: dual GIP and GLP‑1 receptor agonism for combined metabolic effects.
• Dosing: once weekly injection with stepwise titration—refer to specific product labeling.
• Brand examples: Mounjaro (type 2 diabetes), Zepbound (weight management in some regions).
• Prescribe and monitor through qualified healthcare providers; not a substitute for comprehensive lifestyle and medical care.

Research Use Only Disclaimer

Products sold by SoCo Peptides are intended strictly for laboratory research purposes only.

These compounds are not intended for human consumption, veterinary use, household use, cosmetic use, or therapeutic application. They are not drugs, foods, or dietary supplements and have not been evaluated or approved by the FDA.

By purchasing from this website, the customer represents that they are a qualified researcher or laboratory professional and understand the risks associated with handling research materials.

All products must be handled by trained professionals in appropriate research facilities and in accordance with all applicable laws and regulations.

SoCo Peptides makes no guarantees or claims regarding safety, effectiveness, or medical benefit.